4985-92-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Formyl-5-Picoline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new organic compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Formyl-5-Picoline serves as a crucial building block for the creation of agrochemicals, playing a significant role in the synthesis of compounds that can enhance crop protection and yield.
Used as a Reagent in Chemical Reactions:
2-Formyl-5-Picoline is utilized as a reagent in a variety of chemical reactions due to its reactive nature, facilitating the production of diverse organic materials and compounds for research and industrial applications.

InChI:InChI=1/C7H7NO/c1-6-2-3-7(5-9)8-4-6/h2-5H,1H3

Upstream product

• 589-93-5 2,5-dimethylpyridine 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 1121-60-4 pyridine-2-carbaldehyde 
• 4986-05-4 2,5-dimethylpyridine N-oxide 
• 55876-82-9 5-methyl-2-pyridinecarboxylic acid-ethyl ester 
• 1620-77-5 5-methylpicolinonitrile 
• 3430-13-5 5-bromo-2-methylpyridine 
• 661458-29-3 5-methyl-2-pyridylmagnesium bromide 
• 772-71-4 2-acetoxymethyl-5-methyl pyridine 
• 22940-71-2 2-hydroxymethyl-5-methylpyridine 

Downstream Products

• 647840-29-7 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-(5-methyl-2-pyridyl)propionate 
• 647840-28-6 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(tert-butoxycarbonylamino)-3-(5-methyl-2-pyridyl)-2-triisopropylsilyloxypropionate 
• 675137-66-3 (4-dipropylaminobutyl)-(4-{[(1H-imidazol-2-ylmethyl)-(5-methylpyridin-2-ylmethyl)amino]methyl}benzyl)carbamic acid t-butyl ester 
• 675137-68-5 N-(4-dipropylaminomethylphenyl)-4-{[(5-methylpyridin-2-ylmethyl)amino]methyl}benzamide 
• 1250831-75-4 8-benzoyl-3-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]-8-azabicyclo[3.2.1]octan-3-ol 
• 1251052-84-2 8-benzoyl-3-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]-8-azabicyclo[3.2.1]octan-3-ol 
• 1250831-79-8 9-benzoyl-3-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]-9-azabicyclo[3.3.1]nonan-3-ol 
• 1251052-89-7 9-benzoyl-3-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]-9-azabicyclo[3.3.1]nonan-3-ol 
• 1250831-52-7 1-benzoyl-4-[[[(5-methylpyridin-2-yl)methyl]amino]methyl]-piperidin-4-ol 

Relevant academic research and scientific papers

Methyl Scanning and Revised Binding Mode of 2-Pralidoxime, an Antidote for Nerve Agent Poisoning

Organophosphorus nerve agents (OPNAs) inhibit acetylcholinesterase (AChE) and, despite the Chemical Weapons Convention arms control treaty, continue to represent a threat to both military personnel and civilians. 2-Pralidoxime (2-PAM) is currently the only therapeutic countermeasure approved by the United States Food and Drug Administration for treating OPNA poisoning. However, 2-PAM is not centrally active due to its hydrophilicity and resulting poor blood-brain barrier permeability; hence, these deficiencies warrant the development of more hydrophobic analogs. Specifically, gaps exist in previously published structure activity relationship (SAR) studies for 2-PAM, thereby making it difficult to rationally design novel analogs that are concomitantly more permeable and more efficacious. In this study, we methodically performed a methyl scan on the core pyridinium of 2-PAM to identify ring positions that could tolerate both additional steric bulk and hydrophobicity. Subsequently, SAR-guided molecular docking was used to rationalize hydropathically feasible binding modes for 2-PAM and the reported derivatives. Overall, the data presented herein provide new insights that may facilitate the rational design of more efficacious 2-PAM analogs.

A catalytic oxidation heterocyclic aromatic primary alcohol for the preparation of heterocyclic aromatic aldehyde

The invention provides a method for preparing heterocyclic aromatic aldehyde by catalytically oxidizing heterocyclic aromatic primary alcohol. The method takes dioxovanadium nitrate as a catalyst and air as an oxidant; under a normal pressure condition, the heterocyclic aromatic primary alcohol is high-selectively oxidized into the heterocyclic aromatic aldehyde. The method provided by the invention has a high oxidization yield and a byproduct is water, so that the method is green, economical and environment-friendly; reaction conditions are moderate and the operation is simple. A catalysis system takes the air as the oxidant and non-metal metal as a catalyst, reaction conditions are moderate and the oxidization efficiency is high; the catalysis system is green and economical and can be used for efficiently catalyzing the heterocyclic aromatic primary alcohol into the corresponding heterocyclic aromatic aldehyde. Compared with a noble metal catalysis system and a catalysis system containing nitrogen-oxygen free radicals, the catalysis system has low oxidization reaction cost and has very high application value.

Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds

Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

Cobalt(II)-based Metalloradical Activation of 2-(Diazomethyl)pyridines for Radical Transannulation and Cyclopropanation

A new catalytic method for the denitrogenative transannulation/cyclopropanation of in-situ-generated 2-(diazomethyl)pyridines is described using a cobalt-catalyzed radical-activation mechanism. The method takes advantage of the inherent properties of a CoIII-carbene radical intermediate and is the first report of denitrogenative transannulation/cyclopropanation by a radical-activation mechanism, which is supported by various control experiments. The synthetic benefits of the metalloradical approach are showcased with a short total synthesis of (±)-monomorine.

Confined Pyrolysis within Metal-Organic Frameworks to Form Uniform Ru3 Clusters for Efficient Oxidation of Alcohols

Here we report a novel approach to synthesize atomically dispersed uniform clusters via a cage-separated precursor preselection and pyrolysis strategy. To illustrate this strategy, well-defined Ru3(CO)12 was separated as a precursor by suitable molecular-scale cages of zeolitic imidazolate frameworks (ZIFs). After thermal treatment under confinement in the cages, uniform Ru3 clusters stabilized by nitrogen species (Ru3/CN) were obtained. Importantly, we found that Ru3/CN exhibits excellent catalytic activity (100% conversion), high chemoselectivity (100% for 2-aminobenzaldehyde), and significantly high turnover frequency (TOF) for oxidation of 2-aminobenzyl alcohol. The TOF of Ru3/CN (4320 h-1) is about 23 times higher than that of small-sized (ca. 2.5 nm) Ru particles (TOF = 184 h-1). This striking difference is attributed to a disparity in the interaction between Ru species and adsorbed reactants.

Electronic Effects on Narcissistic Self-Sorting in Multicomponent Self-Assembly of Fe-Iminopyridine meso-Helicates

Small changes in the electron donating ability of coordinating groups have substantial effects on the multicomponent self-assembly of Fe (II)-iminopyridine-based meso-helicate complexes. Both the nature of the internal diamine core and the terminal formyl

Optimized strategies to synthesize β-cyclodextrin-oxime conjugates as a new generation of organophosphate scavengers

A new generation of organophosphate (OP) scavengers was obtained by synthesis of β-cyclodextrin-oxime derivatives 8-12. Selective monosubstitution of β-cyclodextrin was the main difficulty in order to access these compounds, because reaction onto the olig

HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES

The present disclosure relates to compounds having the general formula (I) wherein Q represents a five membered heteroaryl group. The compoungs are selective 5-HT1 a modulators and are useful for treating several diseases.

N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

The mechanism of the (bispidine)copper(ii)-catalyzed aziridination of styrene: A combined experimental and theoretical study

Experimental and DFT-based computational results on the aziridination mechanism and the catalytic activity of (bispidine)copper(I) and -copper(II) complexes are reported and discussed (bispidine = tetra- or pentadentate 3,7-diazabicyclo[3.1.1]-nonane derivative with two or three aromatic N donors in addition to the two tertiary amines). There is a correlation between the redox potential of the copper(II/I) couple and the activity of the catalyst. The most active catalyst studied, which has the most positive redox potential among all (bispidine)-copper(II) complexes, performs 180 turnovers in 30 min. A detailed hybrid density functional theory (DFT) study provides insight into the structure, spin state, and stability of reactive intermediates and transition states, the oxidation state of the copper center, and the denticity of the nitrene source. Among the possible pathways for the formation of the aziridine product, the stepwise formation of the two N-C bonds is shown to be preferred, which also follows from experimental results. Although the triplet state of the catalytically active copper nitrene is lowest in energy, the two possible spin states of the radical intermediate are practically degenerate, and there is a spin crossover at this stage because the triplet energy barrier to the singlet product is exceedingly high.